Low sexual desire can be difficult to discuss, especially when it impacts emotional health, relationships, or self-esteem. Bremelanotide is one prescription therapy that has offered an additional option for treating certain types of hypoactive sexual desire disorder (HSDD) in women who are experiencing ongoing problems with sexual desire. This category of treatment relates to a peptide that is commonly known as PT-141 or Nexxana Bremelanotide.Bremelanotide is not like medications that mainly work on blood flow or hormone levels. Instead, it works on melanocortin receptors in signalling in the brain. This difference makes it an interesting option for eligible premenopausal women, but there are important limitations to its effectiveness, safety profile and approved uses.Nexxana Bremelanotide is a bremelanotide-based prescription product associated with Nexxana Desire. Nexxana Desire is a medication intended to treat women’s low sexual desire. Bremelanotide is a synthetic peptide acting on melanocortin receptors. It is also known as PT-141 and is the active ingredient in the FDA-approved prescription drug Vyleesi.www.facebook.com/NexxanaBremelanotide
